NASDAQ:AVTX Avalo Therapeutics Q3 2023 Earnings Report $9.34 -0.31 (-3.21%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$9.30 -0.04 (-0.43%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Avalo Therapeutics EPS ResultsActual EPS-$26.40Consensus EPS -$264.00Beat/MissBeat by +$237.60One Year Ago EPSN/AAvalo Therapeutics Revenue ResultsActual Revenue$0.24 millionExpected Revenue$1.00 millionBeat/MissMissed by -$760.00 thousandYoY Revenue GrowthN/AAvalo Therapeutics Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call DateWednesday, November 8, 2023Conference Call Time6:00PM ETUpcoming EarningsAvalo Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Avalo Therapeutics Earnings HeadlinesAvalo Therapeutics to Participate in Upcoming Investor ConferencesAugust 27 at 7:00 AM | globenewswire.comBrokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $30.00August 27 at 2:29 AM | americanbankingnews.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.August 29 at 2:00 AM | Brownstone Research (Ad)Cantor Fitzgerald Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight RecommendationAugust 16, 2025 | msn.comAvalo Therapeutics initiated with an Overweight at Cantor FitzgeraldAugust 15, 2025 | msn.comAvalo gains as Cantor initiates with bullish view on lead assetAugust 15, 2025 | msn.comSee More Avalo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avalo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalo Therapeutics and other key companies, straight to your email. Email Address About Avalo TherapeuticsAvalo Therapeutics (NASDAQ:AVTX), a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.View Avalo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures Upcoming Earnings Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Micron Technology (9/24/2025)Costco Wholesale (9/25/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access